FDA Greenlights Blueprint Medicines’ Ayvakit for Rare Disease Treatment
Blueprint Medicines had a great start to 2020, bagging its very first FDA approval. Its kinase inhibitor, Ayvakit (avapritinib), won the agency’s nod for treating adults with an unresectable or …
Read More